Premaitha uses the latest advances in DNA sequencing technology for non-invasive prenatal screening tests. IONA uses complex statistical analyses to determine the likelihood that a fetus is carrying a disorder such as Down’s syndrome or other prenatal genetic abnormalities. The opportunity to grow IONA in Asian markets is well recognised and the strategic acquisition of Yourgene Bioscience will accelerate this. Meanwhile, Premaitha has moved quickly to expand the availability of IONA th
17 Mar 2017
Expanding global distribution network
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Expanding global distribution network
- Published:
17 Mar 2017 -
Author:
Martin Hall -
Pages:
12
Premaitha uses the latest advances in DNA sequencing technology for non-invasive prenatal screening tests. IONA uses complex statistical analyses to determine the likelihood that a fetus is carrying a disorder such as Down’s syndrome or other prenatal genetic abnormalities. The opportunity to grow IONA in Asian markets is well recognised and the strategic acquisition of Yourgene Bioscience will accelerate this. Meanwhile, Premaitha has moved quickly to expand the availability of IONA th